1)Freifeld AG, et al:Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer;2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 52:427-431, 2011
2)Bodey GP, et al:Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328-340, 1966
3)Klastersky J, et al:The Multinational Association for Supportive Care in Cancer risk index;A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038-3051, 2000
4)Baden LR, et al:Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 14:882-913, 2016
5)Nesher L, Rolston KV:The current spectrum of infection in cancer patients with chemotherapy ralated neutropenia. Infection 42:5-13, 2014
6)Shelburne SA, et al:Development and validation of a clinical model to predict the presence of β-lactam resistance in viridans group streptococci causing bacteremia in neutropenic cancer patients. Clin Infect Dis 59:223-230, 2014